New hope for Tough-to-Treat breast cancer: experimental drug enters final testing phase
NCT ID NCT06519370
Summary
This study is testing a new drug called FDA018-ADC for people with advanced triple-negative breast cancer that has returned or worsened after standard taxane chemotherapy. It will compare the new drug to standard chemotherapy options chosen by the patient's doctor. The main goals are to see if the new drug helps patients live longer without their cancer getting worse and if it is safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200000, China
Conditions
Explore the condition pages connected to this study.